BIOS Memory SPV I, LP's Form 4 filing
Cognition Therapeutics Inc (CGTX) · filed Nov 29, 2022
- Accession no.
- 0001104659-22-122625
- Filed
- Nov 29, 2022, 7:02 AM ET
- Trade date
- Nov 28, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market purchases total $42.6K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| BIOS Memory SPV I, LPCIK 0001643749 | Director, 10% Owner |
| BIOS Fund I, LPCIK 0001697316 | Director, 10% Owner |
| BIOS Fund I QP, LPCIK 0001700297 | Director, 10% Owner |
| BIOS Fund II, LPCIK 0001714576 | Director, 10% Owner |
| BIOS Fund II QP, LPCIK 0001716869 | Director, 10% Owner |
| Fletcher Aaron G.L.CIK 0001789490 | Director, 10% Owner |
| Bios Equity Partners II, LPCIK 0001813313 | Director, 10% Owner |
| Bios Equity Partners, LPCIK 0001813314 | Director, 10% Owner |
| BIOS Advisors GP, LLCCIK 0001813844 | Director, 10% Owner |
| BIOS Capital Management, LPCIK 0001813845 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 28, 2022 | Common Stock | PPurchaseAcquired | +1,973 | $2.65F5 | +$5,227.86 | 326,733 | Indirect | Duplicate filing |
| Nov 28, 2022 | Common Stock | PPurchaseAcquired | +12,220 | $2.65F5 | +$32,379.33 | 2,021,906 | Indirect | Duplicate filing |
| Nov 28, 2022 | Common Stock | PPurchaseAcquired | +1,871 | $2.65F5 | +$4,957.59 | 309,748 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.64 to $2.65, inclusive. The reporting persons undertake to provide to Cognition Therapeutics Inc., any security holder of Cognition Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
Referenced by the price of 3 transactions in Table I.
Remarks
This Form 4 is the first of two Forms 4 filed relating to the same event. The Form 4 has been split into two filings because there are more than 10 reporting persons in total, and the SEC's EDGAR filing system limits a single Form 4 to a maximum of 10 reporting person. The second Form 4 was filed by Leslie W. Kreis, Jr. as the designated filer.